Tucson, Ariz — HTG, Inc, a provider of molecular technology solutions, has closed a Series D financing round, netting $15.7 million. The new financing will be used to fuel the growth and adoption of HTG’s multi-plex gene expression testing platform for validation and clinical applications across different therapeutic areas. HTG’s qNPA platform is in use at major academic and cancer research centers as well as big pharma.

The company says that the cash infusion will help drive additional utilization across these areas as well as into new high growth molecular diagnostic opportunities. The company will also be looking to hire additional personnel in 2011 including sales and marketing, operations and development scientists with particular experience working in diagnostics.

“HTG had a breakthrough year in 2010 achieving significant milestones in our commercial adoption, expanding our product solutions and building a pipeline of diagnostic tests and we are now positioned to accelerate our momentum, “said TJ Johnson, CEO of HTG. “The financial investment, and confidence, from both new, and current investors, is a true testament to our management team’s ability to execute against our growth plans and bring the value of HTG’s testing platform beyond the research phase into the clinical setting.”